# Wave Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wave-life-sciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.wavelifesciences.com
- Total disclosed funding: $84M
- Latest round: Series B (Aug 18, 2015)
- Investors on record: 9

## About

Based in Massachusetts, US, and founded in 2012 by co-founder Greg Verdine, Wave Life Sciences Ltd., a.k.a. Wave Life Sciences operates as a clinical-stage biotechnology company that focuses on designing, developing, and commercializing ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. In December 2023, Wave Life Sciences Ltd. raised USD 100 million in a private placement, selling 20 million shares at USD 5 per share on the Nasdaq Global Select Market under the ticker symbol WVE. As of May 2024, Paul Bolno is the CEO of the company.

Wave Life Sciences leverages its proprietary PRISM platform to develop RNA medicines that treat a wide range of disorders. PRISM combines various modalities, innovative chemistry, and human genetics insights to create oligonucleotides designed to engage messenger RNA (mRNA) and address diseases by repairing, restoring, or reducing proteins. The platform allows for the modulation of transcriptional diversity, targeting different cell types, and utilizing established manufacturing and regulatory processes. The company’s key programs include WVE-006 for Alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease.

## Funding rounds

- Series B, Aug 18, 2015, $66M — New Leaf Venture Partners, Fidelity Investments, Jennison Associates, Foresite Capital, Redmile Group, RA Capital Management, Cormorant Asset Management, Clough Capital Partners
- Series A, Feb 2, 2015, $18M — RA Capital Management, SNBL

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- SNBL — Series A
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Jennison Associates — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Clough Capital Partners — Series B